BE530472A - - Google Patents
Info
- Publication number
- BE530472A BE530472A BE530472DA BE530472A BE 530472 A BE530472 A BE 530472A BE 530472D A BE530472D A BE 530472DA BE 530472 A BE530472 A BE 530472A
- Authority
- BE
- Belgium
- Prior art keywords
- adrenochrome
- weight
- mono
- para
- oxime
- Prior art date
Links
- RPHLQSHHTJORHI-UHFFFAOYSA-N Adrenochrome Chemical compound O=C1C(=O)C=C2N(C)CC(O)C2=C1 RPHLQSHHTJORHI-UHFFFAOYSA-N 0.000 claims description 31
- 239000000243 solution Substances 0.000 claims description 27
- 150000003839 salts Chemical class 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 15
- 239000002253 acid Substances 0.000 claims description 12
- 230000002439 hemostatic effect Effects 0.000 claims description 11
- 159000000000 sodium salts Chemical class 0.000 claims description 10
- 239000007864 aqueous solution Substances 0.000 claims description 7
- XSXCZNVKFKNLPR-SDQBBNPISA-N carbazochrome Chemical compound NC(=O)N/N=C/1C(=O)C=C2N(C)CC(O)C2=C\1 XSXCZNVKFKNLPR-SDQBBNPISA-N 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 5
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 5
- 231100000252 nontoxic Toxicity 0.000 claims description 5
- 230000003000 nontoxic effect Effects 0.000 claims description 5
- 229910052700 potassium Inorganic materials 0.000 claims description 5
- 239000011591 potassium Substances 0.000 claims description 5
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 2
- 229960002631 carbazochrome Drugs 0.000 claims 4
- SSCSSDNTQJGTJT-UHFFFAOYSA-N (3,6-dihydroxy-1-methyl-2,3-dihydroindol-5-yl)iminourea Chemical compound CN1CC(O)C2=CC(N=NC(N)=O)=C(O)C=C12 SSCSSDNTQJGTJT-UHFFFAOYSA-N 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 150000003863 ammonium salts Chemical class 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- 230000000740 bleeding effect Effects 0.000 description 6
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 4
- 150000007659 semicarbazones Chemical class 0.000 description 3
- 229960004025 sodium salicylate Drugs 0.000 description 3
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- NRZRRZAVMCAKEP-UHFFFAOYSA-N naphthionic acid Chemical compound C1=CC=C2C(N)=CC=C(S(O)(=O)=O)C2=C1 NRZRRZAVMCAKEP-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 1
- -1 ammonium cations Chemical class 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE530472A true BE530472A (d) |
Family
ID=163113
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE530472D BE530472A (d) |
Country Status (1)
| Country | Link |
|---|---|
| BE (1) | BE530472A (d) |
-
0
- BE BE530472D patent/BE530472A/fr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1203242A (fr) | Procede de preparation de sels derives de l'acide 3- hydroxybutanoique et d'une base organique aminee, et les sels ainsi obtenus | |
| EP0316993B1 (fr) | Compositions pharmaceutiques contenant un dérivé de l'acide 3-hydroxybutanoique choisi parmi les oligomères de cet acide et les esters de cet acide ou de ces oligomères avec du 1,3-butanediol | |
| EP0399903A1 (fr) | Nouvelles compositions à base d'imipramine | |
| CH469659A (fr) | Procédé d'obtention de dérivés du tri-hydroxy-méthyl-aminométhane | |
| CH646412A5 (fr) | Procede de preparation des produits hydrosolubles a base de (+)-catechine et compositions contenant ces produits. | |
| FR2522501A1 (fr) | Isothiosemicarbazones antivirales et leur utilisation pour prevenir une infection fongique | |
| FR2460672A1 (fr) | Preparation de poudre d'acetylsalicylate pour injection | |
| CH644015A5 (fr) | Solution aqueuse injectable a base d'oxytetracycline. | |
| MX2013008151A (es) | Un procedimiento para fabricar un complejo mejorado de cloruro de bencetonio-dialil oxido de disulfuro modificado el complejo obtenido y sus usos. | |
| JPS5835967B2 (ja) | 微細結晶ワルフアリンの製造方法 | |
| CA1312333C (fr) | Sel de strontium, son procede de preparation et les compositions pharmaceutiques le renfermant | |
| BE530472A (d) | ||
| CH664284A5 (en) | Chloroquine medicaments without bitter taste - contain complex of chloroquine with copolymer of methacrylic] acid and methyl methacrylate] | |
| BE1000189A3 (fr) | Preparation pharmaceutique a usage veterinaire. | |
| FR2673842A1 (fr) | Nouvelles compositions liquides a base de derives de la piperidine substitues en 1,4. | |
| WO1981002295A1 (fr) | Phenoxyisobutyrates de moroxydine et medicaments les contenant | |
| BE528966A (d) | ||
| FR2616068A1 (fr) | Procede de stabilisation des principes actifs de produits vegetaux et les compositions pharmaceutiques renfermant lesdits principes actifs stabilises | |
| LU84530A1 (fr) | Procede de preparation d'acide p-butoxyphenylacethydroxamique a l'etat finement divise et composition contenant cet acide | |
| BE887220A (fr) | Compositions antitumeurs | |
| BE533913A (d) | ||
| BE903568A (fr) | Nouveaux composes chimiques a activites antiphlogistiques, antiseptiques et detergentes | |
| BE568289A (d) | ||
| BE876544A (fr) | Composes de type acide p-aminobenzoique-n-l-rhamnoside utiles comme medicaments | |
| BE680914A (d) |